Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.

October 24, 2026| Source: The New England journal of medicine

The standard of care for patients with muscle-invasive bladder cancer continues to evolve. Whether perioperative durvalumab, with or without tremelimumab, plus neoadjuvant enfortumab vedotin is effective in such patients is unknown. In this phase 3 open-label trial, we randomly assigned, in a 1:1:1 ratio, patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy to receive neoadjuvant durvalumab-enfortumab vedotin every 3 weeks for three cycles, followed by radical cystectomy and then adjuvant durvalumab every 4 weeks for nine cycles; neoadjuvant durvalumab-tremelimumab-enfortumab vedotin (tremelimumab for two cycles only), radical cystectomy, and adjuvant durvalumab-tremelimumab (tremelimumab for one cycle only); or radical cystectomy alone (control). The dual primary end points were event-free survival in each of the two durvalumab groups as compared with that in the control group. The two durvalumab groups were not compared with each other. The key secondary end point was overall survival. In total, 233 patients were assigned to the durvalumab-enfortumab vedotin group, 233 to the durvalumab-tremelimumab-enfortumab vedotin group, and 229 to the control group. Estimated event-free survival at 24 months was 63.5% (95% confidence interval [CI], 56.5 to 69.7) with durvalumab-enfortumab vedotin and 45.1% (95% CI, 38.2 to 51.8) with control (hazard ratio for an event or death, 0.51; 95% CI, 0.38 to 0.67; P<0.001); estimated overall survival at 24 months was 78.4% and 69.4%, respectively (hazard ratio for death, 0.58; 95% CI, 0.40 to 0.83; P = 0.003). Estimated event-free survival at 24 months was 60.1% (95% CI, 53.2 to 66.2) with durvalumab-tremelimumab-enfortumab vedotin (hazard ratio for an event or death vs. control, 0.61; 95% CI, 0.47 to 0.80; P<0.001). Grade 3 or higher adverse events occurred in 71.1% of patients in the durvalumab-enfortumab vedotin group (treatment-related, 30.7%), in 79.5% of those in the durvalumab-tremelimumab-enfortumab vedotin group (treatment-related, 44.5%), and in 50.2% of those in the control group. Perioperative durvalumab with or without tremelimumab plus three cycles of neoadjuvant enfortumab vedotin resulted in significantly better event-free survival outcomes than surgery alone. Perioperative durvalumab plus enfortumab vedotin led to significantly better overall survival outcomes than surgery alone. Grade 3 or higher adverse events of any cause were noted in more than half the patients in the durvalumab groups. (Funded by AstraZeneca; VOLGA ClinicalTrials.gov number, NCT04960709; EudraCT number, 2020-005452-38.).

Read the original source →

Related Topics

Cancer Research

Historical trends show more declining than increasing species among European pollinators.

Anthropogenic global change presents a growing threat to insect pollinators. Yet, long-term, continental-scale assessments of their population trends remain limited. Here, we leveraged a curated database of over four million occurrence records, covering 88% of extant bee and hoverfly species in Europe, to assess persistence, richness, and occupancy trends over the past century. Species persistence at the European level was relatively high, with modern records available for 87% of bee and 89% of

Extensive glacier loss in the coterminous United States.

Glaciers populate the mountain ranges of the western conterminous United States and despite their importance to alpine hydrology, their area and volume change have never been comprehensively evaluated. Our study shows that since the mid-twentieth century about one-quarter of the glaciers have disappeared and the overall area and volume are reduced by one-third. The pattern of glacier shrinkage suggests most glaciers in the conterminous United States are largely maintained by local topographic in

Scientists disrupt less but more persistently with career aging.

Disruption describes the extent to which a scientific work overturns the prior knowledge on which it builds and leads to a new line of research. A scientist's tendency to produce disruptive work has been found recently to decline over the career. However, the disruption index captures only how strongly a paper overturns prior work and ignores whether that disruption is later accepted or overturned by subsequent research. The persistent disruption (PD) framework adds this second perspective, iden

Geography of groundwater use and depletion in internationally shared aquifers.

Transboundary aquifers (TBAs) underlie 35% of global groundwater-irrigated cropland, yet few are covered by formal cooperative arrangements. Whether this limited cooperation is consequential depends in part on where groundwater is used within shared aquifers, because pumping far from international borders may generate little cross-border impact. Combining [Formula: see text]116,000 well observations with global irrigation data across all 426 known TBAs, we assess how groundwater use and depletio

Programmable chemoenzymatic synthesis of a keratan sulfate N -glycan library for glycocode decoding.

Keratan sulfate (KS) is a unique and widely distributed glycosaminoglycans family implicated in diverse biological processes. KS features branched glycan architectures with diverse sialylation and sulfation patterns, encoding a vastly expanded chemical and biological space. The limited accessibility of well-defined structures has hindered precise investigations into the KS biological functions. Here we report a programmable chemoenzymatic platform for assembling a 106-membered library of KS N -g